regadenoson (lexiscan) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Regadenoson (Lexiscan), a low affinity agonist of the A2A adenosine receptor, increases coronary blood flow (CBF) and mimics the increase in CBF caused by exercise. Myocardial uptake of the radiopharmaceutical is proportional to CBF creating the contrast required to identify stenotic coronary arteries. It is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. The most common adverse reactions to Lexiscan are dyspnea, headache, flushing, chest discomfort, dizziness, angina pectoris, chest pain, and nausea. Methylxanthines, e.g., caffeine and theophylline, may interfere with the activity of Lexiscan. Aminophylline may be used to attenuate severe and/or persistent adverse reactions to Lexiscan.   NCATS

Chemistry

  • SMILES: O.CNC(=O)c1cnn(c1)c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2
  • InChIKey: CDQVVPUXSPZONN-WPPLYIOHSA-N
  • Mol. Mass: 408.38
  • ALogP: -2.43
  • ChEMBL Molecules:
    regadenoson  
    regadenoson  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$33.8640
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(1-(9-(3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-6-aminopurin-2-yl)pyrazol-4-yl)-n-methylcarboxamide | cvt3146 | cvt 3146 | cvt-3146 | lexiscan | rapiscan | regadenoson | regadenoson anhydrous | regadenson

Organizations (69)

Research & Development (53)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (17)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (28)

Approved Indications (1)


 

Myocardial Perfusion Imaging (approved 2008)

Experimental Indications - Clinical Trial Phases 1-4 (27)


 

Anemia, Sickle Cell (Phase 2)

Angina Pectoris (Phase 4)

Asthma (Phase 4)

Atrial Fibrillation (Phase 2)

Brain Diseases (Early Phase 1)

Cardiomyopathies (Phase 4)

Cardiomyopathy, Hypertrophic (Phase 4)

Cardiovascular Diseases (Phase 2)

Coronary Artery Disease (Phase 4)

COVID-19 (Phase 1/Phase 2)

Diabetes Mellitus, Type 1 (Phase 4)

Graft Rejection (Phase 4)

Healthy Volunteers (Phase 1)

Heart Diseases (Phase 2)

Heart Failure (Phase 4)

Heart Failure, Diastolic (Phase 4)

Heart Transplantation (Phase 4)

Hypertension (Phase 4)

Ischemia (Phase 4)

Kidney Diseases (Phase 4)

Lung Transplantation (Phase 1)

Magnetic Resonance Imaging (Early Phase 1)

Myocardial Ischemia (Phase 4)

Myocardium (Phase 4)

Pneumonia (Phase 1/Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Retinal Artery Occlusion (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 58
  • # of Trial Organizations: 53

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue